Certolizumab Biosimilar – Anti-TNF-Alpha mAb – Research Grade from ProteoGenix; catalogue PX-TA1024; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Certolizumab Biosimilar is a novel monoclonal antibody (mAb) that has gained significant attention in the field of immunotherapy due to its potential as a therapeutic agent for various inflammatory and autoimmune diseases. This biosimilar is a highly specific and potent inhibitor of tumor necrosis factor-alpha (TNF-α), a key pro-inflammatory cytokine involved in the pathogenesis of several chronic inflammatory disorders. In this article, we will delve into the structure, activity, and potential applications of Certolizumab Biosimilar as an anti-TNF-α mAb in research settings.
Certolizumab Biosimilar is a recombinant, fully humanized IgG1 monoclonal antibody that is produced by a mammalian cell expression system. It is composed of two heavy chains and two light chains, each containing a variable and constant region. The variable region of Certolizumab Biosimilar specifically binds to TNF-α, while the constant region mediates effector functions such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).
One unique feature of Certolizumab Biosimilar is the absence of the Fc region, which is responsible for effector functions in other mAbs. This is achieved by replacing the Fc region with a 40 kDa polyethylene glycol (PEG) molecule, resulting in a smaller molecular weight of 90 kDa compared to other anti-TNF-α mAbs. This modification not only enhances the half-life and stability of the antibody, but also reduces the risk of immunogenicity and potential adverse effects.
The main mechanism of action of Certolizumab Biosimilar is the neutralization of TNF-α, a pro-inflammatory cytokine that plays a crucial role in the pathogenesis of various diseases, including rheumatoid arthritis, psoriasis, Crohn’s disease, and ankylosing spondylitis. TNF-α is known to induce inflammation, tissue damage, and bone erosion by activating immune cells and promoting the production of other inflammatory cytokines. By binding to TNF-α, Certolizumab Biosimilar prevents its interaction with its receptors and inhibits downstream signaling pathways, thereby reducing inflammation and disease progression.
Moreover, the PEGylation of Certolizumab Biosimilar also contributes to its activity by prolonging its half-life and reducing its clearance from the body. This allows for a longer duration of action and potentially lower dosing frequency compared to other anti-TNF-α mAbs, making it a more convenient and cost-effective option for patients.
Certolizumab Biosimilar has been extensively studied and has shown promising results in clinical trials for various inflammatory and autoimmune diseases. In particular, it has been approved for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and Crohn’s disease in several countries, including Europe and Japan. It is also being investigated for its potential in other indications such as ulcerative colitis, axial spondyloarthritis, and non-infectious uveitis.
In research settings, Certolizumab Biosimilar is widely used as a tool to study the role of TNF-α in disease pathogenesis and to evaluate the efficacy of anti-TNF-α therapies. Its unique structure and mechanism of action provide a valuable platform for developing new and improved anti-TNF-α mAbs with enhanced properties and reduced side effects.
In summary, Certolizumab Biosimilar is a promising anti-TNF-α monoclonal antibody with a unique
ProteoGenix catalogue number PX-TA1024. For research use only.
Target: Certolizumab Biosimilar – Anti-TNF-Alpha mAb – Research Grade; Clonality: Monoclonal Antibody; Expression system: Mammalian cells; Purity: >85%; Molecular weight: 45kDa; Buffer: PBS pH7.5; Applications: ELISA, WB.
Available configurations: 50ug, 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA |
|---|---|---|---|---|---|---|---|---|
| Certolizumab Biosimilar – Anti-TNF-Alpha mAb – Research Grade |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
